Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 2/20 | 0.57 |
| ▸ | NCF1 | P14598 | 1/20 | 0.50 |
| ▸ | NPC1 | O15118 | 4/20 | 0.47 |
| ▸ | RAB9A | P51151 | 4/20 | 0.47 |
| ▸ | NQO1 | P15559 | 1/20 | 0.47 |
| ▸ | CASP3 | P42574 | 1/20 | 0.47 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | PDGFRB | P09619 | 2/20 | 0.46 |
| ▸ | PDGFRA | P16234 | 2/20 | 0.46 |
| ▸ | F2 | P00734 | 1/20 | 0.46 |
| ▸ | GLA | P06280 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | MMP12 | P39900 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | NQO2 | P16083 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12764703 | 0.86 | EGFR (0.57) | EGFRNCF1NPC1RAB9ACASP3 | |
| Hydrochloric Acid SCHEMBL28061626 | 0.84 | EGFR (0.56) | EGFRNCF1NPC1RAB9ACASP3 | |
| SCHEMBL1161417 | 0.80 | EGFR (0.59) | EGFRNCF1NPC1RAB9ANQO1 | |
| SCHEMBL1571317 | 0.79 | ALDH1A1 (0.59) | EGFRNCF1NPC1RAB9ANQO1 | |
| SCHEMBL3428021 | 0.79 | EGFR (0.57) | EGFRNCF1NPC1RAB9ANQO1 | |
| SCHEMBL17347925 | 0.78 | EGFR (0.53) | EGFRNCF1NPC1RAB9ANQO1 | |
| Hydrochloric Acid SCHEMBL28130485 | 0.77 | EGFR (0.56) | EGFRNCF1NPC1RAB9ANQO1 | |
| Hydrochloric Acid SCHEMBL28007029 | 0.77 | ALDH1A1 (0.57) | EGFRNCF1NPC1RAB9ANQO1 | |
| Hydrochloric Acid SCHEMBL28269991 | 0.77 | NCF1 (0.57) | EGFRNCF1NPC1RAB9ANQO1 | |
| SCHEMBL13400459 | 0.76 | EGFR (0.54) | EGFRNCF1NPC1RAB9ANQO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100121052-A1 | Novel compounds for treating proliferative diseases | JAIN RAMA | 2010-05-13 | — | — | US | disclosed |
| US-7691866-B2 | 2,6-disubstituted quinazolines, quinoxalines, quinolines and isoquinolines and methods of their use as inhibitors of Raf kinase | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2010-04-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100121052-A1 | Novel compounds for treating proliferative diseases | PDK1, PDK2, PDK3 | EGFR 1053/4885NCF1 2041/4885NPC1 922/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.